In addition to histological confirmation of disease hallmarks, GAN DIO-NASH mice reproducibly showed increased levels of plasma biomarkers known to be relevant to NAFLD/NASH diagnosis and assessment of fibrosis risk [41–43], including markers of hepatocellular injury (transaminases, CK-18) and ECM remodeling (MMP-9, TIMP-1). This evidence concerns the gene MMP9 and metabolic dysfunction-associated steatohepatitis.